• Room 06.019 - Medical Biology Centre

    United Kingdom

Accepting PhD Students

PhD projects

Open to PhD applications in the field of cancer research, cancer pharmacology, chemoresistance, cell and molecular biology, transcriptomics, biomarker development and drug discovery. Applications should meet the University's English language requirements, secured a source of funding, and who wish to pursue a research project in a relevant research topic. Exemplar PhD projects are detailed below: Mechanism of Drug activity in cancer https://www.dropbox.com/s/1r3f337i5m6mh32/PhD%20Studentship_HDAC6.pdf?dl=0 Molecular Pharmacology of GPCRs https://www.dropbox.com/s/04vjtc24i8svt3k/PhD%20Studentship_Neropeptide_galin.pdf?dl=0

20002019
If you made any changes in Pure these will be visible here soon.

Research Output 2000 2019

Filter
Abstract
2018

Selective HDAC6 inhibition with ACY-1215 promoted resistance to paclitaxel in epithelial ovarian cancer

Karolina Weiner-Gorzel, Tara Byrne, Alo McGoldrick, Caitlin Beggan, Nazia Faheem, Paula Cunnea, Eugene Dempsey, Sharon O'Toole, John O'Learry, Elaine Kay, Tracy Robson, Amanda McCann& Fiona Furlong, 22 Feb 2018, p. 32. 33 p.

Research output: Contribution to conferenceAbstract

2015

MiR-433 induces cellular senescence rendering ovarian cancer cells less likely to undergo chemotherapy-induced apoptosis

Karolina, W-G., Sharpe, D., Milewska, M., McGoldrick, A., Beggan, C., Faheem, N., Toh, V., Fitzpatrick, P., Murphy, M., Madden, S. F., O'Leary, J., O'Toole, S., Kay, E., Kell, M., McCann, A. & Furlong, F., 15 Feb 2015, p. PMS14.

Research output: Contribution to conferenceAbstract

Cell Aging
Ovarian Neoplasms
Apoptosis
Drug Therapy
Paclitaxel

Resistance to chemotherapy in ovarian cancer is miRrored by the microRNA miR-433-dependent dysregulation of the cell cycle.

Karolina, W-G., Dempsey, E., Milewska, M., McGoldrick, A., Toh, V., Walsh, A., Lindsay, S., Gubbins, L., Cannon, A., Sharpe, D., O'Sullivan, J., Murphy, M., Madden, S. F., Kell, M., McCann, A. & Furlong, F., 26 Feb 2015.

Research output: Contribution to conferenceAbstract

MicroRNAs
Ovarian Neoplasms
Cell Cycle
Drug Therapy
Paclitaxel
2014

MIR-433 Predicts poor response to chemotherapy in ovarian cancer patients by the induction of cellular senescence

K., W-G., Sharpe, D., Milewska, M., Beggan, C., Faheem, N., McGoldrick, A., Toh, V., Madden, S., Fitzpatrick, P., Murphy, M., McCaffrey, J., Harrison, M., Kay, E., Kell, M. R., McCann, A. & Furlong, F., 27 Feb 2014.

Research output: Contribution to conferenceAbstract

Cell Aging
Ovarian Neoplasms
Drug Therapy
Paclitaxel
MicroRNAs
2013

Novel Hypoxia-Associated Markers of Chemoresistance in Ovarian Cancer

L McEvoy, S O'Toole, C Spillane, B Stordal, M Gallagher, C Martin, L Norris, N Gleeson, A McGoldrick, F Furlong, A McCann, O Sheils, J O'Leary, 01 Feb 2013, p. 288A.

Research output: Contribution to conferenceAbstract

Ovarian Neoplasms
Cisplatin
Survival
Biomarkers
Genes
2012

Mitotic Arrest Deficiency Protein 2 (MAD2) and Histone Deacetylase 6 (HDAC6) Present a Complex Relationship in Their Regulation and Expression and Subsequent Impact on Chemoresponsiveness

K. Weiner-Gorzel, E. O'Reilly, A. McGoldrick, P. Fitzpatrick, S. O'Toole, A. Maguire, E. Kay, J. O'Leary, A. McCann, & Furlong, F., 01 Jul 2012, p. S214.

Research output: Contribution to conferenceAbstract

Histone Deacetylase 2
Protein Deficiency
Histone Deacetylases
Paclitaxel
Tubulin
2011

Stabilisation of MAD2 expression through inhibition of miR-433; A novel mechanism for restoring chemo-responsiveness in ovarian tumours

Furlong, F. & Fiona M Furlong, Sine Phelan, Alo McGoldrick, Aoife Maguire, Patricia Fitzpatrick, Sharon O'Toole, Orla Shiels, John J O'Leary, Amanda McCann, 15 Apr 2011, p. LB-338.

Research output: Contribution to conferenceAbstract

Paclitaxel
Ovarian Neoplasms
Neoplasms
Cell Line
Proteins
2010

miR-433 overexpression attenuates the spindle assembly checkpoint response to paclitaxel

Furlong, F., Prencipe, M., McGoldrick, A., McGettigan, P., Carney, D., Doyle, E., W Kay, E. & McCann, A., 2010, p. 35.

Research output: Contribution to conferenceAbstract

M Phase Cell Cycle Checkpoints
Paclitaxel
MicroRNAs
HeLa Cells
Ovarian Neoplasms